预约演示
FibroGen, former employees settle dispute over alleged trade secrets theft
临床3期高管变更专利侵权
Under a settlement, neither FibroGen nor China’s Andao Pharmaceutical or California-based Kind Pharmaceuticals are on the hook for any type of payment or compensation.
Nearly a year and a half aftFibroGenGen slapped a pair of former employees with a lawsuit Kind Pharmaceuticalsts theft, both the plaintiffs and the defendants are walking away from the case little worse for wear.
China’s Andao Pharmaceutical anFibroGenrnia-based Kind Pharmaceuticals, along with the latter company’s CEO and chief scientific officer, Dong Liu, Ph.D., and Shaojing Deng, Ph.D., this week announced a mutual agreement with FibroGen to withdraw legal proceedings in the trade secrets spat.
Neither FibroGen nor Andao or Kind are on the hookKind Pharmaceuticalsment or compensation, according to a press release issued by Kind.FibroGen
FibroGenFibroGenlly sAndaoiu and Deng in December 2022 for allegedly pinching proprietary information and filing improper patents around hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors (HIF-PHIs)—a class of drug used to treat anemia that includes FibroGen’s Astellas- and AstraZeneca-partnered roxadustat.
FibroGenDeng worked as scientists at FibroGen for years. In 2013, two years before leaving FibroGen, Liu founded Kind, according to a couhypoxia-inducible factor prolyl hydroxylase enzymeadership position in 2019.anemiaFibroGenAstraZenecaroxadustat
In its case, FibrHangzhou Andao Pharmaceuticals hatched an “international scheme” to give Kind an “unlawful head start” in order to FibroGenears of research developing and identifying HIF-PHI compounds with clinical efficacy.”
FibroGen origFibroGenought to stop Kind from using its proprietary information and pressure the company to list FibroGen as the true owner on its HIF-PHI patents. FibroGen also wanted compensation and for its former employees to forfeit any profits made from patents they “wrongfully” claimed.
"Kind is pleased that these disputKind Pharman fully and finally resolved,” Liu HIF-PHI a statemenAND017th these disputes behind us, Kind can now focus on advancing its innovative pipAND017of products to the market.”anemiacancer-related anemia
As for FibroGen’s roxadustat, the drug has fallen victim to a string of setbacks in the U.S. that culminated in late February with AstraZeneca returning the rights to FibroGen for the HIF-PHI in a range of territories outside China and South Korea, where it’s approved under the brand name Evrenzo.
The decFibroGenme roxadustatls of a phase 3 trial flop and an FDA complete response letter for roxadustat in anemia associated withAstraZenecadney disease in the U.S.FibroGenHIF-PHIEvrenzo
Outside China and Korea, Astellas has a deal with FibroGen to FDAket Evrenzo in Japan and Europroxadustatanemiachronic kidney disease
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。